Clinical Trials for Small Cell Lung Cancer

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with extensive-stage SCLC: Parts 1–2 enroll those progressed after ≥1 platinum regimen; Part 3 enrolls first-line patients after exactly one cycle of platinum/etoposide plus PD-(L)1. Investigational therapy combines tarlatamab (DLL3×CD3 bispecific T-cell engager) with YL201 (B7-H3–targeting topoisomerase I ADC) with or without anti–PD-L1 (atezolizumab or durvalumab).

ClinicalTrials.gov ID: NCT06898957

DAREONᵀᴹ-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with untreated extensive-stage SCLC (ECOG 0–1) eligible for first-line platinum/etoposide plus anti–PD-L1 receive added BI 764532, a DLL3×CD3 bispecific T‑cell engager that redirects T cells to DLL3‑expressing tumor cells. Dose escalation and expansion evaluate safety/MTD and early efficacy with carboplatin or cisplatin/etoposide plus atezolizumab or durvalumab.

ClinicalTrials.gov ID: NCT06077500

A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Patients With Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with DLL3-positive small cell lung cancer that has progressed after or is intolerant to standard therapies receive ZG006 (alveltamig), a trispecific T‑cell engager targeting two DLL3 epitopes and CD3, in a dose-escalation study. Suitable for ECOG 0–1 patients; key exclusions include active infections, recent immunosuppression, and prior severe immune-mediated events.

ClinicalTrials.gov ID: NCT06592638

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic or inoperable somatostatin receptor–positive tumors (GI NETs, pheochromocytoma/paraganglioma, small cell lung, renal cell, and select head/neck cancers) confirmed by SSTR PET receive [212Pb]VMT-Alpha-NET, an SSTR2-targeted alpha-emitting radioligand (212Pb→212Bi) given IV every 8 weeks for up to 4 cycles, with an optional [203Pb] imaging/dosimetry lead-in. Excludes prior systemic radioligand therapy; allows treated/stable or asymptomatic CNS mets and requires adequate organ function.

ClinicalTrials.gov ID: NCT06479811

A Phase Ib/II Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with relapsed/refractory extensive-stage SCLC after platinum-based chemotherapy (ECOG 0–1) receive paclitaxel plus nelmastobart (hSTC810), a humanized IgG4 monoclonal antibody targeting the immune checkpoint BTN1A1 to restore T‑cell activation. Two dose cohorts (400 mg or 800 mg) are evaluated for safety and signal of efficacy, with key exclusions including uncontrolled CNS disease and active autoimmune or viral hepatitis.

ClinicalTrials.gov ID: NCT06016270

A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with relapsed/refractory small cell lung cancer after prior platinum therapy receive oral Debio 0123 (zedoresertib), a selective WEE1 kinase inhibitor that disrupts S and G2/M checkpoints, combined with carboplatin and etoposide on 21‑day cycles. Requires measurable disease, ECOG 0–1, and excludes significant cardiac/QTc issues, ILD, active infections, and prior WEE1 inhibitor exposure.

ClinicalTrials.gov ID: NCT05815160

Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with extensive-stage SCLC that is SSTR-positive by PET (≥50% of measurable metastases SSTR+) and treatment-naive or ≤1 prior cycle of platinum/etoposide plus PD-L1 inhibitor receive first-line carboplatin/etoposide/atezolizumab combined with RYZ101 (225Ac-DOTATATE), an alpha-emitting radiopharmaceutical targeting SSTR2. Aims to define RP2D and assess safety/early activity of adding SSTR2-targeted alpha therapy to standard chemo-immunotherapy.

ClinicalTrials.gov ID: NCT05595460

A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with extensive-stage SCLC who achieved at least stable disease after 4–6 cycles of first-line platinum/etoposide plus atezolizumab or durvalumab receive maintenance PD-L1 inhibitor with or without iadademstat. Iadademstat is an oral covalent LSD1 (KDM1A) inhibitor that modulates SCLC neuroendocrine programs (e.g., activates NOTCH, suppresses ASCL1); treated/stable brain metastases and controlled HIV/HBV/HCV allowed.

ClinicalTrials.gov ID: NCT06287775

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced solid tumors enriched for neuroendocrine/CNS phenotypes—especially relapsed/refractory SCLC and select high-grade CNS tumors and poorly differentiated NECs—receive the SEZ6-targeted antibody–drug conjugate ABBV-706 (Topoisomerase I inhibitor payload) as monotherapy or combined with the PD‑1 inhibitor budigalimab or platinum chemotherapy (carboplatin/cisplatin). Includes patients with ECOG 0–1 and measurable disease; excludes prior Top1 inhibitor–containing ADCs and significant ILD/pneumonitis; brain metastases allowed per protocol.

ClinicalTrials.gov ID: NCT05599984

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adult patients with non-small cell and small cell lung cancers experiencing oligo-progression while on stable systemic therapy, assessing the addition of locally ablative therapies like stereotactic ablative radiotherapy (SABR) and interventional radiology ablation for up to five or fewer metastatic lesions.

ClinicalTrials.gov ID: NCT06103682